Literature DB >> 1388195

Reconstitution of long-term T helper cell function after zidovudine therapy in human immunodeficiency virus-infected patients.

M Clerici1, A L Landay, H A Kessler, J P Phair, D J Venzon, C W Hendrix, D R Lucey, G M Shearer.   

Abstract

Peripheral blood mononuclear cells from 12 asymptomatic patients infected with immunodeficiency virus (HIV) and 4 patients with AIDS were analyzed before and during therapy with zidovudine for T helper cell (Th) function. Th function improved by more than fourfold to one or more of three stimuli tested in 9 (75%) of 12 asymptomatic patients on zidovudine therapy and in 3 of 4 patients with AIDS. Only 6 (7.4%) of 80 untreated HIV-infected control patients showed spontaneous improvement in Th function (P less than 10(-6)). Improved Th function was detected as early as 5 weeks into therapy in 6 patients and continued to be evident for greater than 1 year after start of therapy in 6 patients and for greater than 2 years in 2 patients. No correlation was observed between improved Th function and changes in CD4+ or CD8+ cell numbers or in levels of serum HIV p24 antigen or beta 2-microglobulin. These results suggest inclusion of in vitro Th function as a useful marker in determining the efficacy of antiretroviral drug therapy of HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388195     DOI: 10.1093/infdis/166.4.723

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Effect of protease therapy on cytokine secretion by peripheral blood mononuclear cells (PBMC) from HIV-infected subjects.

Authors:  A D Kelleher; W A Sewell; D A Cooper
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Viral load, CD4 percentage, and delayed-type hypersensitivity in subjects receiving the HIV-1 immunogen and antiviral drug therapy.

Authors:  R B Moss; F Ferre; A Levine; J Turner; F C Jensen; A E Daigle; S P Richieri; A Truckenbrod; R J Trauger; D J Carlo; J Salk
Journal:  J Clin Immunol       Date:  1996-09       Impact factor: 8.317

3.  Activated memory CD4(+) T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2.

Authors:  J J Mattapallil; Z Smit-McBride; P Dailey; S Dandekar
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Impact of highly active anti-retroviral therapy (HAART) on cytokine production and monocyte subsets in HIV-infected patients.

Authors:  N Amirayan-Chevillard; H Tissot-Dupont; C Capo; C Brunet; F Dignat-George; Y Obadia; H Gallais; J L Mege
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

5.  Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy.

Authors:  R Biselli; V Del Bono; M Anselmo; A Canessa; G Mazzarello; R D'Amelio; D Bassetti
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

Review 6.  Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  Michelle I Wilde; Heather D Langtry
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

7.  Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus.

Authors:  M Clerici; T A Wynn; J A Berzofsky; S P Blatt; C W Hendrix; A Sher; R L Coffman; G M Shearer
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

8.  Effects of stress management on PNI-based outcomes in persons with HIV disease.

Authors:  Nancy L McCain; Barbara A Munjas; Cindy L Munro; R K Elswick; Jo L Wheeler Robins; Andrea Ferreira-Gonzalez; Beverly Baliko; Lisa G Kaplowitz; Evelyn J Fisher; Carleton T Garrett; Kevin E Brigle; Linda C Kendall; Valentina Lucas; Katherine L Cochran
Journal:  Res Nurs Health       Date:  2003-04       Impact factor: 2.228

9.  The breakdown of the cytokine network subsequent to human immunodeficiency virus infection.

Authors:  M Clerici; M L Villa; D Trabattoni; G M Shearer
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.